8-K: Waters Corp Exceeds Expectations in Q3 2024, Raises Full-Year Guidance

Waters Corporation reported strong third-quarter 2024 results, exceeding sales and earnings guidance, and raised its full-year outlook.

Summary

• Waters Corporation announced its financial results for the third quarter of 2024, with sales reaching $740 million, a 4% increase compared to the same period last year.
• The company's GAAP earnings per share (EPS) was $2.71, and non-GAAP EPS was $2.93, both significantly surpassing previous guidance.
• Instrument sales returned to growth, and recurring revenue increased by a high single-digit percentage in constant currency.
• All geographic regions experienced growth, with the pharmaceutical and industrial sectors leading the way.
• Waters has raised its full-year 2024 sales guidance and now expects organic constant currency sales growth to be between -0.9% and -0.3%.
• Full-year non-GAAP EPS guidance has also been raised to a range of $11.67 to $11.87.
• The company anticipates fourth-quarter constant currency sales growth to be between 5% and 7%, with non-GAAP EPS between $3.90 and $4.10.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the company exceeding expectations, raising guidance, and showing growth across all regions and markets. The return to growth in instrument sales and strong recurring revenue growth are also positive indicators. However, the negative impact of currency translation and the overall negative full year sales growth temper the sentiment slightly.

Positives

• The company exceeded both sales and earnings guidance for the third quarter of 2024.
• Instrument sales have returned to growth, indicating a positive shift in customer spending.
• Recurring revenue streams are showing strong growth, providing a stable base for future performance.
• All geographic regions and key markets experienced growth, demonstrating broad-based strength.
• The company has raised its full-year sales and EPS guidance, reflecting confidence in future performance.
• The company's strong commercial execution and competitive product portfolio are contributing to its success.

Negatives

• Currency translation is expected to negatively impact full-year sales growth by 1.2% and full-year non-GAAP EPS by approximately 3%.
• The company's full-year 2024 reported sales growth is still expected to be in the range of -0.8% to -0.2%, despite the raised guidance.

Risks

• The company faces risks related to foreign currency exchange rate fluctuations, which could negatively impact the translation of non-U.S. operating results.
• Global economic, sovereign, and political conditions, including trade regulations and geopolitical instability, could affect the company's performance.
• Changes in inflation and interest rates could impact the company's financial results.
• The company is exposed to risks associated with the ongoing conflicts between Russia and Ukraine and in the Middle East.
• The Chinese government's tightening of restrictions on procurement by government-funded customers could pose a challenge.
• The company's ability to access capital and maintain liquidity in volatile market conditions is a risk.
• The company faces risks related to cybersecurity and technology, including potential breaches of security measures.
• The company is subject to increased regulatory burdens, particularly with respect to the U.S. Food and Drug Administration and U.S. Environmental Protection Agency.

Future Outlook

The company has raised its full-year 2024 sales and EPS guidance, expecting continued growth in the fourth quarter, with constant currency sales growth between 5% and 7% and non-GAAP EPS between $3.90 and $4.10.

Management Comments

• Dr. Udit Batra, President & CEO, stated that the exceptional third-quarter results were fueled by new product adoption and improved customer spending trends.
• Dr. Batra also noted that instruments returned to growth sooner than expected, particularly in liquid chromatography sales to pharma and industrial customers.
• Dr. Batra expressed confidence in the long-term outlook for Waters, citing strong commercial execution, a competitive product portfolio, and excellent operational performance.

Industry Context

Waters Corp's strong performance in Q3 2024, particularly the return to growth in instrument sales and the high single-digit growth in recurring revenue, suggests a positive trend in the analytical instruments and software sector. This performance could indicate a broader recovery in customer spending within the life sciences, materials, food, and environmental sciences industries that Waters serves.

Comparison to Industry Standards

• Waters Corp's 4% sales growth in Q3 2024 is a positive sign, especially when compared to some competitors who may be experiencing slower growth or even declines in certain segments.
• Thermo Fisher Scientific, a major competitor, reported a 3% organic revenue growth in their most recent quarter, making Waters' 4% growth look slightly better.
• Agilent Technologies, another competitor, has seen varying growth rates across its different business segments, with some areas experiencing stronger growth than others, making Waters' broad-based growth across all regions and markets a notable achievement.
• The return to growth in instrument sales for Waters is a key indicator, as this segment has been under pressure for many companies in the industry. This suggests that Waters is successfully navigating market challenges and capitalizing on new product adoption.
• Waters' high single-digit growth in recurring revenue is also a positive sign, as this provides a stable and predictable revenue stream, which is highly valued by investors. This is comparable to other companies in the sector that are focusing on building recurring revenue models.

Stakeholder Impact

• Shareholders will likely react positively to the better-than-expected results and raised guidance.
• Employees may feel more secure due to the company's strong performance and positive outlook.
• Customers may benefit from the company's continued investment in product innovation and service.
• Suppliers may see increased demand for their products and services due to the company's growth.
• Creditors may view the company as a lower risk due to its improved financial performance.

Next Steps

• The company will host a conference call to discuss the third-quarter results on November 1, 2024.
• The company will continue to focus on commercial execution, product innovation, and operational performance to achieve its raised full-year guidance.
• The company will monitor and manage the impact of foreign currency exchange rate fluctuations on its financial results.

Key Dates

Keywords

financial results, earnings, sales growth, constant currency, EPS, instruments, recurring revenue, pharmaceutical, industrial, guidance, Waters Corporation